| Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations (NCT06245837) | AstraZeneca | 2024-03-20 |
| Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM (NCT06327815) | AstraZeneca | 2024-03-15 |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer (NCT06267729) | AstraZeneca | 2024-03-12 |
| HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council (NCT06125314) | AstraZeneca | 2024-03-05 |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (NCT06346392) | AstraZeneca | 2024-03-04 |
| A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension (NCT06168409) | AstraZeneca | 2024-03-01 |
| A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US) (NCT06744374) | AstraZeneca | 2024-02-29 |
| A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants (NCT06194032) | AstraZeneca | 2024-02-29 |
| STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma (NCT06465485) | AstraZeneca | 2024-02-28 |
| A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service (NCT06261567) | AstraZeneca | 2024-02-27 |
| Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (NCT05925530) | AstraZeneca | 2024-02-22 |
| A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors (NCT06271837) | AstraZeneca | 2024-02-22 |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (NCT06283966) | AstraZeneca | 2024-02-21 |
| An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604 (NCT06157255) | AstraZeneca | 2024-02-16 |
| A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK (NCT06269484) | AstraZeneca | 2024-02-15 |
| Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) (NCT06380738) | AstraZeneca | 2024-02-14 |
| A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (NCT06040099) | AstraZeneca | 2024-02-13 |
| A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece (NCT06185660) | AstraZeneca | 2024-02-09 |
| A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPD (NCT06172777) | AstraZeneca | 2024-02-08 |
| Study of AZD9829 in CD123+ Hematological Malignancies (NCT06179511) | AstraZeneca | 2024-01-31 |
| AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. (NCT06137144) | AstraZeneca | 2024-01-23 |
| IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US (NCT05970263) | AstraZeneca | 2024-01-19 |
| A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia (NCT06173570) | AstraZeneca | 2024-01-19 |
| A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil (NCT06008353) | AstraZeneca | 2024-01-18 |
| A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors (NCT06130553) | AstraZeneca | 2024-01-18 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia (NCT06238466) | AstraZeneca | 2024-01-16 |
| A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients (NCT06099236) | AstraZeneca | 2024-01-15 |
| A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD (NCT06075095) | AstraZeneca | 2024-01-11 |
| A Study to Assess Multidomain Endpoints of an ECG Patch (NCT06243029) | AstraZeneca | 2024-01-08 |
| A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population (NCT06419413) | AstraZeneca | 2024-01-08 |
| Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD (NCT06192004) | AstraZeneca | 2024-01-05 |
| hATTR Polyneuropathy in Russia (NCT06365593) | AstraZeneca | 2023-12-29 |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia (NCT06137118) | AstraZeneca | 2023-12-29 |
| MultIceNtre Non-intERVentional Study for Efficacy,Safety Evaluation of BREZTRI in Pts With COPD in RussiA (NCT06422676) | AstraZeneca | 2023-12-29 |
| Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia (NCT06414746) | AstraZeneca | 2023-12-29 |
| Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia (NCT06338839) | AstraZeneca | 2023-12-28 |
| A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma (NCT06245551) | AstraZeneca | 2023-12-22 |
| Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs (NCT06175637) | AstraZeneca | 2023-12-20 |
| Observational Secondary Data Study Describing Treatment With Dapagliflozin Among Adult Chronic Kidney Disease Patients (NCT06203704) | AstraZeneca | 2023-12-20 |
| Observational Study Protocol: LIVER-R (NCT06252753) | AstraZeneca | 2023-12-19 |
| TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause (NCT06172751) | AstraZeneca | 2023-12-15 |
| A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (NCT06084884) | AstraZeneca | 2023-12-14 |
| A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (NCT06129864) | AstraZeneca | 2023-12-14 |
| REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania (NCT06170671) | AstraZeneca | 2023-12-13 |
| A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (NCT05951959) | AstraZeneca | 2023-12-13 |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 (NCT06219941) | AstraZeneca | 2023-12-13 |
| An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan (NCT06156982) | AstraZeneca | 2023-12-06 |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma (NCT06106945) | AstraZeneca | 2023-12-05 |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (NCT06188520) | AstraZeneca | 2023-12-05 |
| A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment (NCT06147830) | AstraZeneca | 2023-12-04 |
| Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil (NCT06231693) | AstraZeneca | 2023-12-04 |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (NCT06109779) | AstraZeneca | 2023-12-04 |
| EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy (NCT06194825) | AstraZeneca | 2023-12-01 |
| Chronic Kidney Disease Registry Platform Study (NCT06117852) | AstraZeneca | 2023-11-28 |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) (NCT06103864) | AstraZeneca | 2023-11-23 |
| A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension (NCT06034743) | AstraZeneca | 2023-11-22 |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (NCT06120491) | AstraZeneca | 2023-11-21 |
| A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants (NCT06138795) | AstraZeneca | 2023-11-20 |
| Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant. (NCT06139991) | AstraZeneca | 2023-11-16 |
| Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA (NCT06020014) | AstraZeneca | 2023-11-16 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants (NCT06115967) | AstraZeneca | 2023-11-15 |
| A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (NCT06112379) | AstraZeneca | 2023-11-14 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese (NCT06132841) | AstraZeneca | 2023-11-13 |
| A Real-world, Multi-center, Prospective, Observational Study for PNH in China (NCT06154512) | AstraZeneca | 2023-11-10 |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (NCT06097728) | AstraZeneca | 2023-11-09 |
| Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) (NCT05925803) | AstraZeneca | 2023-11-08 |
| Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) (NCT06087835) | AstraZeneca | 2023-11-07 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants (NCT06122714) | AstraZeneca | 2023-11-07 |
| A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers (NCT06103877) | AstraZeneca | 2023-11-01 |
| Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs. (NCT06046534) | AstraZeneca | 2023-10-27 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants. (NCT06093542) | AstraZeneca | 2023-10-25 |
| A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (NCT06067828) | AstraZeneca | 2023-10-24 |
| A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (NCT05984277) | AstraZeneca | 2023-10-24 |
| Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya (NCT05898412) | AstraZeneca | 2023-10-06 |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (NCT05952557) | AstraZeneca | 2023-10-05 |
| Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NCT06057064) | AstraZeneca | 2023-09-29 |
| A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (NCT06151964) | AstraZeneca | 2023-09-29 |
| The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA) (NCT06056778) | AstraZeneca | 2023-09-28 |
| Tezepelumab PRO Study (NCT05922891) | AstraZeneca | 2023-09-27 |
| Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease (NCT06053424) | AstraZeneca | 2023-09-25 |
| Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (NCT06040086) | AstraZeneca | 2023-09-22 |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (NCT06079671) | AstraZeneca | 2023-09-22 |
| A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (NCT05938270) | AstraZeneca | 2023-09-21 |
| PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan (NCT05573893) | AstraZeneca | 2023-09-12 |
| Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND) (NCT05903989) | AstraZeneca | 2023-09-11 |
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study (NCT05825365) | AstraZeneca | 2023-08-31 |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma (NCT06023589) | AstraZeneca | 2023-08-24 |
| Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (NCT05771480) | AstraZeneca | 2023-08-16 |
| BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (NCT05943106) | AstraZeneca | 2023-08-11 |
| eVusheld Assessment reaL wORld Effectiveness in DoD Health System (NCT05569408) | AstraZeneca | 2023-08-10 |
| Acalabrutinib Real World Italian obSErvational Study -ARISE (NCT06205498) | AstraZeneca | 2023-08-08 |
| Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants (NCT05932641) | AstraZeneca | 2023-07-31 |
| A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria (NCT05967806) | AstraZeneca | 2023-07-31 |
| OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain (NCT06068049) | AstraZeneca | 2023-07-28 |
| A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab (NCT06042049) | AstraZeneca | 2023-07-27 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers.. (NCT05955183) | AstraZeneca | 2023-07-27 |
| Secondary Data Analysis of Patients at Risk for CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic Behaviour, Treatment Patterns and Patient Characteristics (NCT05953701) | AstraZeneca | 2023-07-26 |
| A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) (NCT05924880) | AstraZeneca | 2023-07-21 |
| Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece (NCT05915182) | AstraZeneca | 2023-07-21 |
| AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) (NCT05850234) | AstraZeneca | 2023-07-20 |